摘要
目的 :为了解不同剂量利培酮对精神分裂症不同症状群的疗效有无差异。方法 :将符合CCMD Ⅱ R精神分裂症诊断标准的患者随机分 4组 ,用 2 ,3,4 ,5mg固定剂量的利培酮治疗。于用药前、用药 1周末、2周末、4周末、6周末、8周末、12周末进行PANSS评分 ,对各组的PANSS总分及减分率、各症状群总分及减分率进行比较、分析。结果 :共有 173例入组 ,16 0例完成 12周观察。统计分析显示 12周末的PANSS总分 4组均较治疗前有显著降低 ,减分率、有效率、显效率 4组间均无显著性差异。阳性、阴性、一般精神病理 3个分量表分析 ,12周末各剂量组间减分率、有效率、显效率无显著差异。临床治愈率阴性症状各组间无显著差异 ,阳性症状 3,5mg显著高于 2 ,4mg组 ,一般精神病理症状 3mg显著高于 4mg组 ,显示 3mg对 3个症状群的改善都是最好的。反应缺乏、思维障碍、激活性、偏执、抑郁 5个症状群比较分析也显示 3mg对各症状群的疗效最好。结论 :不论是PANSS总分 ,还是不同的因子分析 ,3mg都是起效最早、疗效最好的 ,3mg利培酮是治疗精神分裂症的最佳剂量。当患者以思维障碍、阳性症状为主要表现时 ,利培酮用量以 35mg·d-1为宜 ;阴性症状为主时 2 4mg·d-1为宜 ;抑郁症状突出时 2 3mg·d-1为宜。
Objective: To investigate the effects of different fixed dose of Risperdone on the clinic symptoms in the treatment of schizophrenia. Methods: This was a prospective open-label study. 173 patients with the diagnosis of schizophrenia were randomly assigned to 2, 3, 4 and 5 mg·d -1 treatment groups and treated for 12 weeks. The efficacy was evaluated with the positive and negative symptom scale(PANSS). Results: After 12 weeks, 160 patients completed the study. Each treatment group brought about notable clinic improvement, but no significant differences were found in the total score of PANSS and its reduction rate among 4 treatment groups. The 3 mg·d -1 treatment group took significant clinic effect after 1 week, other groups took effect after 2 week.The reduction rate of the positive symptom score was significantly higher in the 3 mg·d -1 and 5 mg·d -1 groups than in 2 mg·d -1 and 4 mg·d -1 groups , the score of the general psychopathology symptom decreased significantly in the 3 mg·d -1 group than in the 4 mg·d -1 group. The effect of the 3 mg·d -1 Risperdone was the best in treatment of reaction deficit, thought disorder, irritability, paranoid and depression among 4 groups. Conclusion: It is suggested that 3 mg·d -1 Risperdone is the best appropriate dose in the treatment of schizophrenia.
出处
《武汉大学学报（医学版）》
CAS
2004年第5期583-586,共4页
Medical Journal of Wuhan University
关键词
利培酮
精神分裂症
疗效
Risperdone
schizophrenia
efficacy
